tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ravi Mehrotra, 5 are a BUY (100%).
Analyst Ravi Mehrotra, carries an average stock price target met ratio of 100% that have a potential upside of 24.3% achieved within 100 days.
Ravi Mehrotra’s has documented 10 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 19-Nov-2014.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 11/22/2013. The price target of $290 was fulfilled within 3 days with a profit of $4.38 (1.53%) receiving and performance score of 5.11.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
Since 08-Jan-2026
$190
$25.58 (15.56%)
$199
12 days ago
(08-Jan-2026)
0/5 (0%)
$4 (2.15%)
Hold
Since 09-Dec-2024
$185
$20.58 (12.52%)
$180
13 days ago
(07-Jan-2026)
11/30 (36.67%)
$2.39 (1.31%)
200
Hold
Since 21-Oct-2021
$180
$15.58 (9.48%)
$125
13 days ago
(07-Jan-2026)
16/24 (66.67%)
$-2.61 (-1.43%)
195
Hold
Since 31-Oct-2024
$156
$-8.42 (-5.12%)
$149
1 months 8 days ago
(12-Dec-2025)
24/48 (50%)
$-16.5 (-9.57%)
266
Hold
Since 02-Aug-2024
$190
$25.58 (15.56%)
$140
1 months 10 days ago
(10-Dec-2025)
10/17 (58.82%)
$12.45 (7.01%)
223
What Year was the first public recommendation made by Ravi Mehrotra?
